Trial Profile
A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Vorinostat (Primary) ; Temozolomide
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions
- 18 Jul 2023 Status changed from active, no longer recruiting to completed.
- 03 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 06 Oct 2021 Planned primary completion date changed from 1 Dec 2021 to 18 Oct 2021.